- 专利标题： Compounds inhibiting leucine-rich repeat kinase enzyme activity
-
申请号： US14912761申请日： 2014-08-18
-
公开(公告)号： US09718818B2公开(公告)日： 2017-08-01
- 发明人: Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
- 申请人： MERCK SHARP & DOHME CORP. , Duane DeMong , Thomas J. Greshock , Ronald K. Chang , Xing Dai , Hong Liu , John A. McCauley , Wei Li , Kallol Basu , Jack D. Scott , Michael Miller
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 Keith D. MacMillan; John C. Todaro
- 国际申请： PCT/US2014/051401 WO 20140818
- 国际公布： WO2015/026683 WO 20150226
- 主分类号： A61K31/44
- IPC分类号： A61K31/44 ; C07D471/04 ; C07D498/04 ; C07D519/00 ; C07D487/04
摘要：
The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
公开/授权文献
信息查询
